Massive Bleeding in Children With Cancer or Hematopoietic… : Pediatric Critical Care Medicine
Children ages 0–21 years old with malignancy and/or HCT and massive bleeding admitted from January 1, 2017, to December 31, 2021. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Demographics, oncologic history, laboratory values, interventions, and PICU outcomes were collected. One hundred fifty-two bleeding episodes from 135 patients were analyzed. The median (interquartile range [IQR]) age was 7 years (2–14 yr). Forty-three percent (58/135) were female sex. Nineteen percent of children (26/135) had death attributable to hemorrhage. Forty percent had solid tumors and one-third had undergone at least one HCT. The majority of bleeding events occurred in the PICU (81/152, 53%). The median (IQR) platelet count at time of bleeding was 52 × 109/L (24–115 × 109/L), prothrombin time 18.5 seconds (15.2–24.8 s), activated partial thromboplastin time 42.2 seconds (33.2–56.0 s), and international normalized ratio 1.51 (1.21–2.11). To treat these bleeding events, 99% (148/152) of the time chil
